A Study of LY2127399 in Participants With Systemic Lupus Erythematosus

Inclusion Criteria:

- Clinical diagnosis of SLE as defined by American College of Rheumatology (ACR)
criteria

- Have positive antinuclear antibodies (ANA)

- Agree not to become pregnant throughout the course of the trial

- Have a screening SELENA-SLEDAI score ≥6. (The participant must be actively exhibiting
all the symptoms scored on the screening SELENA-SLEDAI on the day of screening.)

Exclusion Criteria:

- Have active severe Lupus kidney disease

- Have active Central Nervous System or peripheral neurologic disease

- Have received intravenous immunoglobulin (IVIg) within 180 days of randomization

- Have active or recent infection within 30 days of screening

- Have had a serious infection within 90 days of randomization

- Have evidence or test positive for Hepatitis B

- Have Hepatitis C

- Are human immunodeficiency virus (HIV) positive

- Have evidence of active or latent tuberculosis (TB)

- Presence of significant laboratory abnormalities at screening

- Have had a malignancy in the past 5 years, except for cervical carcinoma in-situ or
basal cell or squamous epithelial skin cell that were completely resected with no
reoccurrence in the 3 yrs prior to randomization

- Have received greater than 40 mgs of prednisone or equivalent in the past 30 days

- Have changed your dose of antimalarial drug in the past 30 days

- Have changed your dose of immunosuppressive drug in the past 90 days

- Have previously received rituximab